Current status and perspectives on vaccine development against dengue virus infection

Jisang Park; Ju Kim; Yong-Suk Jang

doi:10.1007/s12275-022-1625-y

Articles

Page Path: HOME > J. Microbiol > Volume 60(3); 2022 > Article

Review
Current status and perspectives on vaccine development against dengue virus infection: Jisang Park ^1,2, Ju Kim ³, Yong-Suk Jang ^1,2,3; Journal of Microbiology 2022;60(3):247-254
DOI: https://doi.org/10.1007/s12275-022-1625-y
Published online: February 14, 2022

¹Department of Bioactive Material Sciences and the Research Center of Bioactive Materials, Jeonbuk National University, Jeonju 54896, Republic of Korea, ²Innovative Research and Education Center for Integrated Bioactive Materials, Jeonbuk National University, Jeonju 54896, Republic of Korea, ³Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju 54896, Republic of Korea¹Department of Bioactive Material Sciences and the Research Center of Bioactive Materials, Jeonbuk National University, Jeonju 54896, Republic of Korea, ²Innovative Research and Education Center for Integrated Bioactive Materials, Jeonbuk National University, Jeonju 54896, Republic of Korea, ³Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Jeonbuk National University, Jeonju 54896, Republic of Korea

Corresponding author: Yong-Suk Jang , Tel: +82-63-270-3343,

Received: 1 December 2021 • Revised: 12 January 2022 • Accepted: 12 January 2022

prev next

21 Views
0 Download
0 Crossref
29 Scopus

Full Article

Abstract

Dengue virus (DENV) consists of four serotypes in the family Flaviviridae and is a causative agent of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome. DENV is transmitted by mosquitoes, Aedes aegypti and A. albopictus, and is mainly observed in areas where vector mosquitoes live. The number of dengue cases reported by the World Health Organization increased more than 8-fold over the last two decades from 505,430 in 2000 to over 2.4 million in 2010 to 5.2 million in 2019. Although vaccine is the most effective
method
against DENV, only one commercialized vaccine exists, and it cannot be administered to children under 9 years of age. Currently, many researchers are working to resolve the various problems hindering the development of effective dengue vaccines; understanding of the viral antigen configuration would provide insight into the development of effective vaccines against DENV infection. In this review, the current status and perspectives on effective vaccine development for DENV are examined. In addition, a plausible direction for effective vaccine development against DENV is suggested.

Keywords: Lactobacillus crispatus PMC 201;Mycobacterium tuberculosis;anti-tuberculosis effect;microbiome;probiotics

Figure & Data

References

Citations

Citations to this article as recorded by

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Current status and perspectives on vaccine development against dengue virus infection

J. Microbiol. 2022;60(3):247-254. Published online February 14, 2022

DOI: https://doi.org/10.1007/s12275-022-1625-y

Related articles